Compare Amgen, Inc. (AMGN) vs Chubb Ltd (CB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Chubb Ltd — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Chubb Ltd trades at $350.16 (market cap $134.91B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | CB | |
|---|---|---|
Market Cap | $196.12B | $134.91B |
Sector | Health | Financials |
52-Week High | $388.16 | $361.17 |
52-Week Low | $271.18 | $265.99 |
Enterprise Value | $241.41B | $155.96B |
Dividend Yield | 2.77% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Chubb Limited (CB) trades at $347.83, showing minimal daily movement with a slight 0.01% gain. The stock exhibits bullish technical signals from moving averages and strong fundamental health, including consistent earnings beats and a net income margin of 18.46%. Recent news highlights disciplined capital deployment and premium growth, while the upcoming Q2 2026 earnings report on July 22, 2026, is highly anticipated.
The outlook remains positive given analyst consensus favoring Buy ratings and a price target of $354.69, suggesting modest upside. Key risks include catastrophe losses and softer commercial pricing, but the company's robust balance sheet and rising investment income support long-term growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →
